TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15795705
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg losartan
Study: 11850708
Drug: Heparin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin plus ursodiol
Study: 21459941
Drug: Milnacipran 100
Normalized name: milnacipran 100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milnacipran 100 mg/day (PBO:MLN100)
Study: 15632102
Drug: Metformin 2,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 2,000 mg/day
Study: 9647682
Drug: Dual task
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual task during encoding with concurrent articulatory suppression
Study: 2661738
Drug: Whole-brain irradiation
Normalized name: pork brain preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-brain irradiation (6020 rads) concurrent with chemotherapy
Study: 26821769
Drug: 0.5 kg/mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 kg/mg ketamine and 0.2 kg/mg ketamine
Study: 22537767
Drug: Oral estradiol
Normalized name: estradiol Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral estradiol (2 mg/day)
Study: 21934534
Drug: Oral estradiol
Normalized name: estradiol Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral estradiol combined with medroxyprogesterone acetate (MPA; 5 mg/day)
Study: 8487512
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (engaged strictly in skill activities daily)
Study: 30571543
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of pyridostigmine 60 mg and atomoxetine 18 mg
Study: 17515448
Drug: Atomoxetine 18
Normalized name: atomoxetine 18 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine 18 mg
Study: 31563866
Drug: Monthly ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Monthly ranibizumab
Study: 21797667
Drug: Brimonidine 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brimonidine 0.1% eye drops twice daily
Study: 21797667
Drug: Placebo eye
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo eye drops administered to the other eye twice daily
Study: 17651149
Drug: High-dose inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose inhaled corticosteroids (ICS)
Study: 15100679
Drug: Medium-dose or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-dose or high-dose inhaled corticosteroids (ICS) or oral corticosteroids
Study: 2501775
Drug: Topical mupirocin
Normalized name: mupirocin Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical mupirocin
Study: 31595704
Drug: Tablet formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet formulation (R)
Study: 31595704
Drug: Disintegrating tablet
Normalized name: Clozapine Orally Disintegrating Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disintegrating tablet formulation (T)
Study: 19063816
Drug: Olopatadine 0.2%
DrugBank: Olopatadine (DB00768)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olopatadine 0.2% ophthalmic solution
Study: 10657867
Drug: No G-CSF
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No G-CSF (Control)
Study: 9305321
Drug: 2000 mg
Normalized name: bran 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000 mg citicoline
Study: 9305321
Drug: Citicoline (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citicoline (all doses)
Study: 31701163
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (40 IU)
Study: 28914726
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior therapy for insomnia specific to bipolar disorder (CBTI‐BP)
Study: 22098090
Drug: Probiotic yoghurt
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic yoghurt (200 g/d for 9 weeks)
Study: 22098090
Drug: Conventional yoghurt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional yoghurt (200 g/d for 9 weeks)
Study: 17287908
Drug: Vitamin K2
Normalized name: Vitamin K2
DrugBank: Menaquinone 6 (DB14936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K2 (MK-4, menatetrenone) 45 mg/day
Study: 7908358
Drug: Very-low-dose warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very-low-dose warfarin
Study: 2650797
Drug: TP-5 50
Normalized name: OTX-TP
DrugBank: Travoprost (DB00287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: TP-5 50 mg three times a week for 3 weeks
Study: 25311447
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin D(3) 5000 IU daily
Study: 6383832
Drug: Verapamil (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (0.1 mg kg-1 i.v. on admission followed by 120 mg perorally t.i.d. for 6 months)
Study: 23586456
Drug: Cognitive-behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral treatment incorporating aspects of imaginal desensitization and motivational interviewing
Study: 11574441
Drug: Fidarestat (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fidarestat (1 mg daily for 52 weeks)
Study: 8800732
Drug: Quadruple therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple therapy plus methotrexate (n = 17)
Study: 8800732
Drug: Quadruple therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple therapy (n = 19)
Study: 27760494
Drug: Angle-class, midline-displacement,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angle-class, midline-displacement, crossbite, or orthodontic therapy
Study: 23274597
Drug: 2.8 mg·kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.8 mg·kg BM of PSE
Study: 17369520
Drug: Intramuscular electrical
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular electrical stimulation (n = 32)
Study: 25170553
Drug: Quadrivalent human
Normalized name: PAPILLOMAVIRUS HUMAN QUADRIVALENT VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent human papillomavirus vaccine (HPV4) before concomitantly administered vaccines
Study: 25170553
Drug: Quadrivalent human
Normalized name: PAPILLOMAVIRUS HUMAN QUADRIVALENT VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent human papillomavirus vaccine (HPV4) after concomitantly administered vaccines
Study: 26721134
Drug: Acupuncture-moxibustion treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture-moxibustion treatment
Study: 15373869
Drug: Topical spray
Normalized name: Topical Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical spray
Study: 7653745
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (BDP) 100 micrograms four times daily
Study: 2892143
Drug: Enalapril (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (20 mg daily) + Hydrochlorothiazide (50 mg daily)
Study: 2832575
Drug: Enalapril (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (20 mg daily) + Atenolol (50 mg daily)
Study: 2892143
Drug: Beta-blockers and
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blockers and Diuretics
Study: 23849325
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg nifedipine and 32 mg candesartan FDC
Study: 23849325
Drug: Loose combination
Normalized name: loose wheat smut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loose combination of 60 mg nifedipine GITS and 32 mg candesartan
Study: 23849325
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg nifedipine GITS alone
Study: 23849325
Drug: 32 mg
Normalized name: caffeine 32 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 32 mg candesartan alone
Study: 12925476
Drug: Intrathecal diamorphine
Normalized name: Diamorphine
DrugBank: Diamorphine (DB01452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal diamorphine 0.2 mg
Study: 12925476
Drug: Intrathecal diamorphine
Normalized name: Diamorphine
DrugBank: Diamorphine (DB01452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal diamorphine 0.3 mg
Study: 12925476
Drug: Intrathecal diamorphine
Normalized name: Diamorphine
DrugBank: Diamorphine (DB01452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal diamorphine 0.4 mg
Study: 9523865
Drug: F13 (13
Approvals — FDA: no, EMA: no, PMDA: no
Description: F13 (13 g/l protein)
Study: 9523865
Drug: F15 (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: F15 (15 g/l protein)
Study: 8816618
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (GnRH‐a)
Study: 21105835
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive pills (OCPs)
Study: 7714086
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of OCPs and GnRH‐a
Study: 2692963
Drug: 50 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 micrograms ethinyl estradiol (EE) and 1.0 mg norethindrone (NE)
Study: 2692963
Drug: 35 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35 micrograms ethinyl estradiol (EE) and 1.0 mg norethindrone (NE)
Study: 2692963
Drug: 35 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35 micrograms ethinyl estradiol (EE) and 0.5 mg norethindrone (NE)
Study: 29635379
Drug: Apremilast 20
Normalized name: apremilast 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apremilast 20 mg twice a day
Study: 29635379
Drug: Apremilast 30
Normalized name: apremilast 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apremilast 30 mg twice a day
Study: 25779750
Drug: MRI substudy
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRI substudy (both apremilast doses)
Study: 22120252
Drug: Intravenous nimodipine
Normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous nimodipine
Study: 18694222
Drug: Novel combinations
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel combinations of existing open source solutions
Study: 9625339
Drug: Theophylline (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (4 mg/kg then 2 mg/kg twice daily)
Study: 7908778
Drug: Azelastine 2
Normalized name: azelastine 2.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelastine 2 sprays/nostril q24h
Study: 7908778
Drug: Azelastine 2
Normalized name: azelastine 2.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelastine 2 sprays/nostril q12h
Study: 7908778
Drug: Oral chlorpheniramine
Normalized name: chlorpheniramine Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral chlorpheniramine maleate 12 mg q12h
Study: 3261158
Drug: Fiberoptic injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fiberoptic injection sclerotherapy (FIS)
Study: 26456372
Drug: Roflumilast 100
Normalized name: Roflumilast
DrugBank: Roflumilast (DB01656)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Roflumilast 100 μg, 250 μg, or 500 μg once daily
Study: 26456372
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (BDP) 400 μg or 500 μg twice daily
Study: 14550680
Drug: Nefazodone (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefazodone (maximum dose 600 mg/day)
Study: 11108760
Drug: Traditional upper-extremity
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional upper-extremity (UE) therapies
Study: 1305840
Drug: Paracetamol (with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (with or without codeine)
Study: 6289058
Drug: Ranitidine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (150 mg twice a day)
Study: 29846604
Drug: 1% transdermal
Normalized name: Androgel 1% Transdermal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% transdermal testosterone gel applied daily for 3 years
Study: 29846604
Drug: Placebo applied
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo applied daily for 3 years
Study: 23150707
Drug: Concurrent chemoradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiation with fluorouracil (FU) plus mitomycin (MMC)
Study: 23150707
Drug: Induction plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction plus concurrent fluorouracil (FU) plus cisplatin (CDDP)
Study: 29124549
Drug: Single-agent chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-agent chemotherapy with surgical resection
Study: 27811855
Drug: Home-based walking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based walking exercise training and weekly exercise counseling
Study: 12391059
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (20 g/day for 4 days, then 2 g/day for 17 days)
Study: 19730217
Drug: Epsilon aminocaproic
Normalized name: Epsilon Aminocaproic Acid
DrugBank: Aminocaproic acid (DB00513)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epsilon aminocaproic acid (EACA) 100 mg/kg
Study: 8646867
Drug: Betamethasone-17,21-dipropionate ointment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betamethasone-17,21-dipropionate ointment, 0.05%
Study: 30412068
Drug: Pharmacologic agents
Normalized name: COPD pharmacologic substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacologic agents
Study: 27344046
Drug: Budesonide/formoterol (BF)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol (BF) 320/9 μg delivered by Spiromax
Study: 27344046
Drug: Budesonide/formoterol (BF)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol (BF) 320/9 μg delivered by Turbuhaler
Study: 22313076
Drug: Granisetron 10
Normalized name: GRANISETRON 10MG/0.4ML INJ,SYRINGE KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron 10 µg/kg diluted in 10 ml saline 0.9% intravenously (group 1, n=40)
Study: 22313076
Drug: Placebo (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (10 ml 0.9% saline, group 2, n=40)
Study: 20002510
Drug: Adapted U.S.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adapted U.S. model of pharmaceutical care
Study: 16257339
Drug: Gefitinib (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib (250 mg/day) plus best supportive care
Study: 2200966
Drug: Corticosteroids (prednisolon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids (prednisolon 2 mg/kg/day IV initially, then prednisone orally for 3 weeks)
Study: 19770624
Drug: ezetimibe 10
Normalized name: ezetimibe 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ezetimibe 10 mg daily
Study: 15196292
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous eletriptan (n = 24)
Study: 15196292
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose of sumatriptan (6 mg subcutaneously, n = 18)
Study: 11602853
Drug: Basiliximab (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basiliximab (20 mg, intravenously on days 0 and 4)
Study: 899874
Drug: Doleron (combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doleron (combination tablet containing propoxyphene chloride, acetyl salicylic acid, and phenazone) taken with a standardized breakfast meal
Study: 899874
Drug: Doleron (combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doleron (combination tablet containing propoxyphene chloride, acetyl salicylic acid, and phenazone) taken on an empty stomach
Study: 899874
Drug: Doleron (combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doleron (combination tablet containing propoxyphene chloride, acetyl salicylic acid, and phenazone)
Study: 25575246
Drug: AeroEclipse II
Normalized name: AeroEclipse II BAN Nebulizer
Approvals — FDA: no, EMA: no, PMDA: no
Description: AeroEclipse II BAN nebulizer with 20-second inhalation
Study: 25575246
Drug: EW nebulizer
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: EW nebulizer with 20-second inhalation
Study: 3898920
Drug: Continuous low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Continuous low-dose intravenous infusion of lidocaine (2 mg/kg) for 24 hours after surgery
Study: 24989775
Drug: GAL-021 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GAL-021 at 0.96 mg kg(‐1) h(‐1) for 1 h
Study: 22527222
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of PAI‐1 variants with known genetic thrombophilias
Study: 31595565
Drug: Methazolamide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methazolamide (100 mg twice daily)
Study: 26689783
Drug: Rivaroxaban (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (2.5 mg twice daily)
Study: 24699093
Drug: Gadolinium contrast
Normalized name: gadolinium
DrugBank: Gadolinium (DB12091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gadolinium contrast agent administration
Study: 19097848
Drug: 10-day antibiotic
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day antibiotic therapy
Study: 20185560
Drug: 14-day antibiotic
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-day antibiotic therapy
Study: 6274471
Drug: suloctidil 300
Normalized name: suloctidil
DrugBank: Suloctidil (DB13340)
Approvals — FDA: no, EMA: no, PMDA: no
Description: suloctidil 300 mg per day
Study: 28643922
Drug: Growing subjects
Normalized name: minoxidil
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Growing subjects (G)
Study: 28643922
Drug: Overall comparison
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall comparison of G vs NG
Study: 23350589
Drug: Corticocancellous allograft
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticocancellous allograft block with saline solution
Study: 23350589
Drug: Standard guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard guided bone regeneration with saline solution
Study: 22732511
Drug: Antibiotics alone;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics alone; n=54
Study: 22732511
Drug: Antibiotics plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics plus albumin; n=56
Study: 16143188
Drug: Long-term treatment
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term treatment (5 years)
Study: 12403182
Drug: Active modalities
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active modalities (various treatments)
Study: 12403182
Drug: Anterior repositioning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anterior repositioning appliance therapy
Study: 12403182
Drug: Flat plane
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flat plane splint therapy
Study: 7805235
Drug: Zankiren HCl
Normalized name: Chlorpromazine Hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zankiren HCl (10 to 250 mg)
Study: 7250172
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination of sotalol and hydrochlorothiazide (6.4:1 ratio)
Study: 25862350
Drug: Capecitabine 825
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 825 mg/m² twice daily on days 1-21 every 4 weeks
Study: 25862350
Drug: S-1 40-60
Normalized name: DIMETHICONOL/TRIMETHYLSILOXYSILICATE CROSSPOLYMER (40/60 W/W; 1000000 PA.S)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 40-60 mg twice daily on days 1-28 every 6 weeks
Study: 23799280
Drug: Ibuprofen (200-400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (200-400 mg)
Study: 7863248
Drug: 2 x
Normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x 300 mg/d nizatidine (n = 90)
Study: 8212757
Drug: nizatidine 150
Normalized name: nizatidine 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: nizatidine 150 mg nocte (n = 116) in prophylactic trial
Study: 8212757
Drug: 2 x
Normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x 150 mg nizatidine daily (n = 121) in prophylactic trial
Study: 3535187
Drug: Daily short
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily short course chemotherapy (6-month) with regimens containing streptomycin, isoniazid, rifampicin, and pyrazinamide in the initial phase; isoniazid plus rifampicin or isoniazid plus rifampicin and/or pyrazinamide in the continuation phase.
Study: 3535187
Drug: Daily short
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily short course chemotherapy (6-month)
Study: 31318258
Drug: Perceived momentum
Normalized name: aspirin / phenyltoloxamine citrate Oral Tablet [Momentum tradename]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perceived momentum in sequential events
Study: 31318258
Drug: Events that
Normalized name: Evenity
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Events that break streaks (e.g., incorrect guesses)
Study: 31004325
Drug: Needle-free insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Needle-free insulin injector
Study: 24089542
Drug: Conventional insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional insulin pen
Study: 28734823
Drug: Simvastatin 80
Normalized name: simvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 80 mg daily for up to 28 days
Study: 14668658
Drug: Lidocaine injection
Normalized name: lidocaine Injection
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine injection (control group)
Study: 9267946
Drug: Dopexamine infusion
Normalized name: dopexamine
DrugBank: Dopexamine (DB12313)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopexamine infusion at 6.0 microg/kg/min
Study: 9267946
Drug: Dopexamine infusion
Normalized name: dopexamine
DrugBank: Dopexamine (DB12313)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopexamine infusion at 3.0 microg/kg/min